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Abstract
Background: Coffee consumption has been associated with reduced risk of developing type 2 diabetes mellitus
(T2DM) however, the mechanism for this association has yet to be elucidated. Non-alcoholic fatty liver disease
(NAFLD) characterizes and predicts T2DM yet the relationship of coffee with this disorder remains unclear. Our aim
was to investigate the associations of coffee with markers of liver injury in 1005 multi-ethnic, non-diabetic adults in
the Insulin Resistance Atherosclerosis Study.
Methods: Dietary intake was assessed using a validated 114-item food frequency questionnaire. Alanine
aminotransferase (ALT), aspartate aminotransferase (AST) and fetuin-A were determined in fasting blood samples
and the validated NAFLD liver fat score was calculated. Multivariate linear regression assessed the contribution of
coffee to variation in markers of liver injury.
Results: Caffeinated coffee showed significant inverse associations with ALT (β = −0.08, p = 0.0111), AST (β = −0.05,
p = 0.0155) and NAFLD liver fat score (β = −0.05, p = 0.0293) but not with fetuin-A (β = 0.04, p = 0.17). When the highest
alcohol consumers were excluded, these associations remained (ALT β = −0.11, p = 0.0037; AST β = −0.05, p = 0.0330;
NAFLD liver fat score β = −0.06, p = 0.0298). With additional adjustment for insulin sensitivity, the relationship with ALT
remained significant (ALT β = −0.08, p = 0.0400; AST β = −0.03, p = 0.20; NAFLD liver fat score β = −0.03, p = 0.27). There
were no significant associations of decaffeinated coffee with liver markers.
Conclusions: These analyses indicate a beneficial impact of caffeinated coffee on liver morphology and/or function,
and suggest that this relationship may mediate the well-established inverse association of coffee with risk of T2DM.
Keywords: Coffee, Caffeine, Decaffeinated, Type 2 diabetes, ALT, AST, NAFLD liver fat score, Fetuin-A, Liver enzymes,
Insulin resistance atherosclerosis study
Background
Coffee consumption has consistently been associated
with a reduction in risk of developing type 2 diabetes
mellitus (T2DM), however few studies have attempted
to identify the pathophysiological pathway underlying
this relationship [1, 2]. Exploring the impact of coffee
consumption on major risk factors for T2DM will be im-
portant in uncovering potential mediating relationships
underlying the observed beneficial association of coffee
with this chronic disease. Non-alcoholic fatty liver dis-
ease (NAFLD) has been identified as a predictor of dia-
betes risk according to a meta-analysis of prospective
population-based studies using transaminase concentra-
tions [3]. In addition, three studies reported a significant
association of ultrasound-identified NAFLD with inci-
dent T2DM [4–6]. However, the relationship of coffee
with NAFLD remains unclear [7]. Evidence suggests a
beneficial impact of coffee on the liver in individuals with
alcoholic and viral liver diseases [8–11] and hepatocellular
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carcinoma [8, 9, 12], although the relationship of coffee
with liver markers is largely unstudied in the context of
liver disease of metabolic origin. Existing epidemiological
studies support a beneficial impact of coffee consumption
on the liver in apparently healthy populations, however
the majority of these data were from studies of male popu-
lations in Asia [13–18]. A recent study of participants in
the National Health and Nutrition Examination Survey
(NHANES) extended these investigations to the United
States and reported an inverse association of coffee con-
sumption with liver enzymes, including alanine amino-
transferase (ALT), aspartate aminotransferase (AST),
gamma-glutamyl transferase (GGT) and alkaline phos-
phatase (ALP) [19]. Examining these relationships in a
population with more extensive metabolic characterization,
including insulin resistance and pre-diabetes, would be
informative.
The existing literature on coffee and liver injury
markers is limited in several aspects. First, little is
known about the individual effects of caffeinated vs de-
caffeinated coffee. Xiao et al. (2014) were the first to dif-
ferentiate between caffeinated and decaffeinated coffee
in their examination of the independent relationships of
recent intake, assessed by 24 h recall, of these coffee
types with markers of liver injury [19]. Additional studies
that distinguish between caffeinated and decaffeinated cof-
fee consumption using measures that capture usual, rather
than recent, intake of these coffee types are needed in
order to assess the independent relationships of habitual
intake of coffee with markers of liver injury. Second, pre-
vious investigations focused primarily on associations
of coffee with routinely measured liver enzymes; exam-
ination of coffee’s relationship with other biomarkers of
liver function and biomarker-based scores predictive of
NAFLD would be instructive. Fetuin-A, a biomarker for
inflammation and liver function, has been positively as-
sociated with insulin resistance and an increased risk of
T2DM [20–22]. Investigations of the relationship of cof-
fee consumption with fetuin-A have been limited to two
studies which suggest a beneficial impact of coffee, but
these findings need to be corroborated [20, 23].
Biomarker-based predictive scores derived from simple,
non-invasive, clinical data are emerging as a practical, yet
robust, method for predicting NAFLD [24, 25]. The vali-
dated NAFLD liver fat score was recently identified as
the best non-invasive prediction score for identifying
NAFLD when compared to similar tools [25]. To our
knowledge, associations of coffee with this predictive
score have yet to be examined. In light of these import-
ant knowledge gaps, the objective of the current study was
to investigate the associations of usual caffeinated and de-
caffeinated coffee consumption with markers of NAFLD,
including ALT, AST, fetuin-A, and the validated NAFLD
liver fat score [24], in a multi-ethnic cohort.
Methods
Study population and design
The Insulin Resistance Atherosclerosis Study (IRAS) is
an epidemiological investigation of the relationship of
insulin resistance (IR) with cardiovascular risk factors
in a large multi-ethnic population [26]. The design of
IRAS has been published in detail [26]. Briefly, data
collection was initiated in October 1992 with partici-
pants recruited from four geographic areas in the
United States (San Antonio TX, San Luis Valley CO,
Oakland and Los Angeles CA). The recruitment target
was to achieve equal participation across categories of sex,
ethnicity (non-Hispanic white, Hispanic, African Ameri-
can), age and glucose tolerance status (normal, impaired
glucose tolerance, diabetes). In total, the baseline IRAS
population included 1625 participants, from which written
informed consent was obtained. This study was con-
ducted in accordance with the Helsinki Declaration
and the institutional review boards at Kaiser Perma-
nente Division of Research (Oakland, CA), University
of California (Los Angeles, CA), University of Texas
Health Science Center at San Antonio (San Antonio,
TX), the University of Colorado (Denver, CO), and the
Bowman Gray School of Medicine (Winston-Salem,
NC) approved the project.
For the current cross-sectional study, the population
was restricted to individuals without T2DM, as defined
by the 1999 World Health Organization criteria [27].
Further exclusions were made on the basis of missing
liver enzyme data or extremes of energy intake, result-
ing in a final study population of n = 1005. Fetuin-A
data were not available for all individuals however par-
ticipant characteristics did not differ substantially be-
tween those for which fetuin-A data was available (n =
650) and those for which it was not (n = 355) (data not
shown).
Data collection
Participant assessments were conducted across two
4 h visits approximately 1 week apart and participants
were asked to fast for 12 h prior to each visit [26].
Diabetes status was assessed on the first visit using a
75 g oral glucose tolerance test (OGTT). Blood was
collected for fasting and 2-h glucose samples. IR
was assessed at the second visit using the insulin-
modified frequently sampled intravenous glucose tol-
erance test (FSIGTT), and insulin sensitivity (SI), was
calculated using mathematical modeling methods
(MINMOD version 3.0, 1994, Los Angeles, CA),
as has been described in previous publications [26,
28–30]. Socio-demographic information was collected
by participant report and questionnaires assessed en-
ergy expenditure, alcohol consumption and smoking
behaviours [31].
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Exposure variables
Dietary intake over the past year was assessed using a
validated interviewer-administered 114-item food fre-
quency questionnaire (FFQ) modified for the IRAS
from the National Cancer Institute’s Health Habits and
History Questionnaire to include a number of regional
and ethnic foods [26, 32]. This measure was validated in
a sub-sample of the population through the administra-
tion of eight 24-h recalls administered on randomly se-
lected days over a 1 year period. Results demonstrated
desirable validity and confirmed the appropriateness of
this instrument for use in this population [31]. Although
the validation did not specifically address coffee, it is
established that coffee drinking behaviour is accurately
captured in FFQs (American women r = 0.8, men r = 0.9,
respectively, vs dietary records) [33, 34].
Caffeinated and decaffeinated coffee consumption
were assessed individually and participants reported on
both the frequency and quantity of consumption [26].
Frequency was reported using a nine category scale with
responses ranging from “never or less than 1 per month”
to “six or more times per day” [35]. Individuals indicated
whether their portion sizes were “small, medium or large
compared with other men or women about your age”
[32]. Frequency and portion size data were integrated in
order to provide a single value reflective of intake by
weighting the intake frequency by a factor of 0.5, 1 or
1.5 for the reported portion size of small, medium or
large, respectively. Thus, one serving of an item reflects
one participant-identified medium serving. Intakes of
caffeinated and decaffeinated coffee were summed for a
measure of total coffee. Categories of vegetable, fruit
and whole grain intakes were calculated according to
groupings established in previous work in IRAS [36].
Nutrient analysis of FFQ data was conducted using the
HHHQ-DIETSYS analysis software (version 3.0, 1993;
National Cancer Institute, Bethesda, MD, USA).
Outcome variables
Fasting blood samples were used to determine markers
of liver injury. Liver enzymes ALT and AST were mea-
sured using standard methods at the central IRAS la-
boratory with a Paramax PLA instrument (Baxter) [37].
Fetuin-A was determined using a sandwich-format im-
munoassay developed by Tethys (Tethys Bioscience,
Emeryville, CA) with antibodies from R&D systems
(Minneapolis, USA). The assay had a detection limit of
0.5 ng/ml and an inter-assay coefficient of variation of
11 %. NAFLD liver fat score was calculated according to
the equation developed and validated by Kotronen et al.
which includes fasting serum insulin, ALT, AST and pres-
ence of the metabolic syndrome (International Diabetes
Federation harmonized definition) [24, 38].
Statistical analysis
Statistical analyses were conducted using SAS version
9.2 (SAS Institute, Cary, NC). Participant characteristics
were tested for differences across categories of total cof-
fee intake. Chi-square tests were used to test differences
in frequencies of categorical variables. For continuous
variables, differences in means were tested using ANOVA
unless the variable was highly skewed. In this case, the
Kruskal-Wallis test for non-parametric variables was used.
Linear regression analyses were conducted to assess
the independent relationships of caffeinated and decaf-
feinated coffee consumption, modeled as continuous
variables, with markers of liver injury. The distributions
of outcome variables were evaluated and natural log
transformations were used for all outcome variables as
they resulted in more normal distributions. Due to the
presence of negative values, a constant of 6.4 was added
to all NAFLD liver fat score data before the transform-
ation. The independent associations of caffeinated and
decaffeinated coffee consumption with outcome vari-
ables were analyzed using staged multivariate models. A
base model adjusted for age, sex, and ethnicity. A second
model additionally adjusted for energy intake and ex-
penditure, BMI, smoking, alcohol consumption and edu-
cation. Finally, a third model additionally adjusted for a
number of dietary factors including whole grain con-
sumption, vegetable and fruit intake, percent of energy
intake from saturated and polyunsaturated fat as well as
intake of the alternate type of coffee consumed (caffein-
ated or decaffeinated), and sugar-sweetened beverages
(regular soda and lemonade/sweetened mineral water).
To test for potential modifiers of the relationship be-
tween coffee consumption and markers of liver injury,
interaction terms were tested for age, sex, ethnicity, BMI
and SI, and were judged to be statistically significant if
the p value was <0.05.
A sensitivity analysis was performed in which multi-
variate linear regression analyses were conducted with
total coffee consumption as the exposure variable. Be-
cause of the well-known association between high alco-
hol consumption and elevations in liver transaminases,
sensitivity analyses were performed in which regression
models were repeated when individuals in the two high-
est categories of alcohol consumption were excluded (≥1
alcoholic drink/day). In addition, a fourth mechanistic re-
gression model which additionally adjusted for insulin sen-
sitivity was added in order to assess the contribution of SI




Participant characteristics by categories of total coffee
consumption are presented in Table 1. In this population,
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Table 1 Participant characteristics by categories of total coffee consumption (n = 1005a)
Total coffee consumption (servings/day)
Variable None >0 to <0.5 0.5 to <1 1 to <2 ≥2 p
n (%) 214 (21.3) 195 (19.4) 377 (37.5) 170 (16.9) 49 (4.9) -
Age (years) 54 (47–62) 54 (47–62) 55 (48–63) 54 (48–60) 54 (46–61) 0.45
Sex, n (%) 0.07
Males 81 (37.9) 82 (42.1) 164 (43.5) 87 (51.2) 26 (53.1)
Females 133 (62.2) 113 (57.9) 213 (56.5) 83 (48.8) 23 (46.9)
Ethnicity, n (%) <0.0001
Non-Hispanic white 99 (46.3) 61 (31.3) 136 (36.1) 83 (48.8) 28 (57.1)
Hispanic 48 (22.4) 45 (23.1) 169 (44.8) 65 (38.2) 17 (34.7)






141 (65.9) 121 (62.1) 264 (70.0) 113 (66.5) 42 (85.7)
Impaired glucose
tolerance
73 (34.1) 74 (37.9) 113 (30.0) 57 (33.5) 7 (14.3)
Highest education
level completed, n (%)
0.0003
≤ Elementary 6 (2.8) 16 (8.2) 36 (9.6) 14 (8.2) 4 (8.2)
≤ High school 61 (28.5) 48 (24.6) 151 (40.1) 45 (26.5) 16 (32.7)
≤ College 114 (53.3) 92 (47.2) 137 (36.3) 76 (44.7) 22 (44.9)
≤ Graduate school 33 (15.4) 39 (20.0) 53 (14.1) 35 (20.6) 7 (14.3)
Smoking status, n (%) <0.0001
Never 130 (60.8) 91 (46.7) 169 (44.8) 56 (32.9) 7 (14.3)
Past 62 (29.0) 75 (38.5) 138 (36.6) 87 (51.2) 21 (42.9)




Never drank 43 (20.1) 13 (6.7) 43 (11.4) 5 (3.0) 2 (4.1)
Ex-drinker 47 (22.0) 23 (11.8) 46 (12.2) 24 (14.2) 6 (12.2)
Very little 38 (17.8) 35 (18.0) 63 (16.8) 24 (14.2) 10 (20.4)
<0.5 drinks/day 45 (21.0) 70 (35.9) 120 (31.9) 54 (32.0) 15 (30.6)
0.5 to <1 drinks/day 15 (7.0) 23 (11.8) 39 (10.4) 20 (11.8) 4 (8.2)
1 to <3 drinks/day 20 (9.4) 27 (13.9) 51 (13.6) 32 (18.9) 9 (18.4)
≥3 drinks/day 6 (2.8) 4 (2.1) 14 (3.7) 10 (5.9) 3 (6.1)
BMI (kg/m2) 27.3 (25.0–30.5) 27.2 (24.6–31.2) 27.5 (24.8–30.6) 27.4 (25.0–30.2) 26.5 (23.6–30.6) 0.49
Waist circumference (cm) 88.8 (80.0–97.3) 89.8 (81.8–97.0) 90.1 (81.5–98.7) 90.9 (81.7–99.1) 89.7 (79.3–97.8) 0.62
Insulin sensitivity
(x 10−4 min−1[μU’ml]−1)
1.5 (0.8–2.8) 1.6 (0.9–2.9) 1.6 (0.9–3.0) 1.8 (0.9–2.9) 2.5 (1.1–3.8) 0.13
Family history of
diabetes, n (%)




1736 (1321–2301) 1596 (1157–2110) 1945 (1366–2337) 1852 (1450–2471) 1902 (1334–2589) 0.0004
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79 % of individuals were consuming at least one type of
coffee. Amounts of coffee consumed however were rela-
tively modest with a median total coffee intake of 0.50
servings/day [interquartile range (IQR), 0.04-0.79]. Ap-
proximately 66 % of the population consumed caffeinated
coffee while decaffeinated coffee intake was less common
with only 28 % of individuals consuming this type. Ethni-
city, level of education and smoking and alcohol consump-
tion behaviours differed significantly across categories of
total coffee consumption (Table 1). The highest category of
total coffee consumption had the lowest proportion of par-
ticipants with impaired glucose tolerance, however SI, BMI,
waist circumference, family history of diabetes and energy
expended did not differ significantly across categories of
total coffee consumption. Energy intake, percent of energy
from saturated fat and regular soda consumption differed
significantly across categories where the highest energy in-
takes and saturated fat consumption were found in the
highest categories of coffee consumption. Caffeinated and
decaffeinated coffee consumption were inversely correlated
(Spearman r = −0.20, p <0.0001). ALT and fetuin-A were
inversely correlated with SI (ALT Spearman r = −0.27,
p <0.0001; fetuin-A Spearman r = −0.16, p <0.0001), and
positively correlated with each other (Spearman r = 0.11,
p = 0.0057).
Regression analyses
Caffeinated coffee consumption was inversely associ-
ated with ALT, AST and NAFLD liver fat score, and, in
the case of ALT, there was a stronger magnitude of as-
sociation across staged multivariate models (Table 2,
model 3: ALT β = −0.08, p = 0.0111; AST β = −0.05, p =
0.0155; NAFLD liver fat score β = −0.05, p = 0.0293).
Caffeinated coffee consumption however, showed no
significant association with fetuin-A (Table 2, model 3:
β = 0.04, p = 0.17). There were no significant associa-
tions of decaffeinated coffee consumption with markers
of liver injury.
Interaction and sensitivity analyses
Associations of coffee with markers of liver injury were
not modified by age, sex, ethnicity, BMI or SI (all
p > 0.05).
Multivariate linear regression analyses were also con-
ducted with total coffee as the exposure variable. For the
liver enzymes, results of regression analyses with total
coffee consumption were consistent with those of caf-
feinated coffee consumption, with significant associa-
tions of total coffee intake with both ALT and AST
(Additional file 1: Table S1, model 3: ALT β = −0.07,
p = 0.0177; AST β = −0.05, p = 0.0131). Total coffee con-
sumption was not however, associated with NAFLD liver
fat score (Additional file 1: Table S1, model 3: β = −0.04,
p = 0.11) or fetuin-A, (Additional file 1: Table S1, model
3: β = 0.02, p = 0.47).
When the heaviest alcohol consumers were ex-
cluded, the significant inverse association of caffein-
ated coffee with ALT, AST and NAFLD liver fat score
Table 1 Participant characteristics by categories of total coffee consumption (n = 1005a) (Continued)
Total energy
expended
(kcal kg−1 year −1)




0.7 (0.2–1.2) 0.6 (0.3–1.1) 0.6 (0.2–1.1) 0.7 (0.3–1.2) 0.5 (0.1–1.0) 0.52
% Energy from
saturated fat
11.9 (9.5–14.1) 11.6 (9.0–13.9) 12.5 (10.3-14.6) 12.7 (11.0–14.8) 12.7 (10.8–14.6) 0.0003
% Energy from
polyunsaturated fat




0.03 (0.0–0.5) 0.03 (0.0–0.1) 0.03 (0.0–0.1) 0.03 (0.0–0.1) 0.07 (0.0–0.3) 0.0313
Markers of liver injury
ALT (units/l) 17.0 (11.0–23.0) 16.0 (12.0–24.0) 16.0 (11.0–22.0) 17.0 (11.0–24.0) 15.0 (9.0–23.0) 0.40
AST (units/l) 21.0 (17.0–26.0) 21.0 (16.0–26.0) 21.0 (17.0–26.0) 21.0 (16.0-25.0) 19.0 (16.0–24.0) 0.56





−0.9 (−2.0, 0.8) −1.1 (−2.1, 0.4) −1.1 (−2.2, 0.3) −1.0 (−2.2, 0.5) −1.8 (−2.7, −0.1) 0.23
aSlight variation across variables
bn = 650
cn = 988
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not only remained, but, in the case of ALT, there was
a stronger magnitude of association compared to the
initial analysis (Table 3, model 3: ALT β = −0.11, p =
0.0037; AST β = −0.05, p = 0.0330; NAFLD liver fat
score β = −0.06; p = 0.0298). With additional adjust-
ment for SI in a fourth (mechanistic) model, the sig-
nificant inverse association of caffeinated coffee with
ALT remained, however the association with AST and
NAFLD liver fat score was attenuated to non-
significance (Table 3, model 4: ALT β = −0.08, p =
0.0400; AST β = −0.03, p = 0.20; NAFLD liver fat score
β = −0.03, p = 0.27). Associations of caffeinated coffee with
fetuin-A (Table 3, model 4: β = 0.03, p = 0.44), and decaf-
feinated coffee with all liver markers remained unchanged
from the original analysis (data not shown).
Discussion
NAFLD has emerged as an important predictor of
T2DM [37, 39] and thus it is of interest to investigate
the relationship of this disorder with coffee consumption
in the context of attempting to identify a potential medi-
ating role on the inverse relationship of coffee with
T2DM. Our findings regarding ALT, AST and NAFLD
liver fat score shed light on a potential mediating rela-
tionship that may underlie this inverse association [1, 2].
Results of the present cross-sectional examination of a
multi-ethnic, non-diabetic cohort reveal significant in-
verse associations of caffeinated coffee consumption
with ALT and AST, and in the case of ALT, there was a
stronger magnitude of association across multivariate
models and with the exclusion of individuals whose
transaminase levels may be affected by alcohol con-
sumption. Analyses also revealed an inverse relationship
of caffeinated coffee with NAFLD liver fat score, a non-
invasive validated tool for identifying NAFLD using rou-
tinely available clinical and laboratory data [24]. These
findings are consistent with accumulating evidence dem-
onstrating a beneficial impact of coffee consumption on
the liver. Specifically, a beneficial effect of coffee on the
risk of NAFLD as defined by elevated liver transami-
nases [40] or abdominal imaging [41, 42], a reduction in
risk of fibrosis associated with coffee consumption in pa-
tients with NAFLD [43] and NASH [44], and inverse as-
sociations of coffee with ALT and GGT [11, 13–19].
Previous studies of associations of coffee with liver en-
zymes however have been conducted largely in Japanese
male populations or among individuals with alcoholic
and viral liver diseases. Investigations of associations of
coffee with liver markers in liver diseases of metabolic ori-
gin (ie. NAFLD) are scarce. Our findings are consistent
with the only other study of healthy individuals conducted
in North America [19] and extend these investigations to
a large multi-ethnic population with more complete meta-
bolic characterization, including directly-measured insulin
resistance and diabetes status assessed by OGTT. Our as-
sessment of usual, rather than recent, intake of caffeinated
and decaffeinated coffee consumption allowed us to better
characterize coffee drinking behavior in this population
and assess the independent relationships of habitual intake
of coffee types with markers of liver injury.
Table 2 Multiple linear regression analysis of the associations of caffeinated and decaffeinated coffee consumption with markers of
liver injury
Outcome per unit increase in
coffee
ALTab ASTab Fetuin-Aac NAFLD liver fat scoread
β (95 % CI) p
value
β (95 % CI) p
value
β (95 % CI) p
value
β (95 % CI) p
value
Caffeinated coffee




0.0200 0.03 (−0.02, 0.09) 0.26 −0.07 (−0.12,
−0.01)
0.0122




0.0148 0.05 (−0.02, 0.11) 0.14 −0.06 (−0.10,
−0.01)
0.0218








Model 1 −0.02 (−0.14, 0.10) 0.80 −0.03 (−0.11, 0.05) 0.42 −0.09 (−0.20,
0.02)
0.12 0.02 (−0.07, −0.12) 0.66
Model 2 −0.01 (−0.13, 0.11) 0.86 −0.03 (−0.11, 0.05) 0.44 −0.10 (−0.21,
0.02)
0.09 0.04 (−0.05, 0.13) 0.36
Model 3 −0.02 (−0.14, 0.09) 0.69 −0.04 (−0.12, 0.04) 0.36 −0.08 (−0.19,
0.04)
0.19 0.03 (−0.06, 0.12) 0.47
Model 1: Age, sex, ethnicity
Model 2: Adjusted as in model 1 + energy intake, energy expenditure, education, BMI, smoking, alcohol consumption
Model 3: Adjusted as in model 2 + whole grain consumption, vegetable intake, fruit intake, % energy from saturated fat, % energy from polyunsaturated fat,
alternate coffee type, regular soft drinks, lemonade/sweetened mineral water
aLog transformation;bn = 1005 with slight variation across models;cn = 650 with slight variation across models;dn = 998 with slight variation across models
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Our findings suggest that caffeinated coffee’s beneficial
impact on NAFLD may potentially mediate its inverse
association with T2DM. The relationship of NAFLD
with IR and oxidative stress is well established [45]. It is
possible that the antioxidant properties of coffee may
help to offset reactive oxygen species, thereby contribut-
ing to a reduction in IR and subsequent fatty acid depos-
ition in the liver [45, 46]. Results of our fourth
mechanistic model support this notion as additional ad-
justment for SI attenuated associations of caffeinated
coffee with markers of liver injury. Interestingly, for
ALT, the more sensitive and liver-specific transaminase,
the association with caffeinated coffee consumption
remained significant in this model suggesting that this
relationship is not entirely explained by SI.
Investigations of the relationship of coffee consump-
tion with fetuin-A are extremely limited [20, 23]. To our
knowledge, only one study has examined the specific re-
lationship of caffeinated coffee with fetuin-A which simi-
larly reported null associations [20].
Our analyses did not identify significant associations
of decaffeinated coffee with markers of liver injury,
which is notable considering the inverse relationship of
decaffeinated coffee with T2DM was shown to be stron-
ger than that of caffeinated coffee in a meta-analysis [1].
It is likely that the lack of significant associations in the
current analysis may be related to the generally modest
consumption of decaffeinated coffee and narrow range
of intakes in this population. The low level of decaffein-
ated coffee consumption in the current study may ex-
plain why our findings of a null association of
decaffeinated coffee with fetuin-A are discordant with
the only other study investigating this relationship [20].
Wedick et al. (2011) reported an inverse association of
decaffeinated coffee with fetuin-A in their randomized
control trial in which individuals consumed 5 6 oz cups
of decaffeinated coffee/day [20]. It is possible that higher
levels of consumption than reported in the current
study are necessary to document this relationship.
Alternatively, it is possible that null associations of de-
caffeinated coffee with liver markers may be explained
by differing mechanistic pathways that are being im-
pacted by these coffee types. It has been suggested for
example that decaffeinated coffee may specifically bene-
fit beta cell function rather than IR, which appears to be
more strongly linked with caffeinated coffee in this co-
hort [35].
The current study has a number of strengths including
its large sample size, multi-ethnic population and de-
tailed measures used to assess participant characteristics
including diabetes status, assessed using the OGTT, and
SI determined by FSIGTT. Further, a validated FFQ was
used to measure usual intake of coffee and nutritional
covariates. Unlike the majority of previous studies, our
FFQ differentiated between caffeinated and decaffeinated
coffee intake offering insight into the relationship of
usual intake of each coffee type with outcome variables.
The examination of multiple markers of liver injury, in-
cluding liver transaminases, fetuin-A, and NAFLD liver
fat score, represents a further strength of this study.
Potential limitations of the current study include the
cross-sectional design as this precludes conclusions be-
ing drawn regarding the causality or the temporal nature
of associations. As an observational study, there is po-
tential for residual confounding. However extensive data
were collected on potential covariates and these vari-
ables were carefully considered in the development of
regression models. The reliance on participant self-
report and the semi-quantitative design of the FFQ may
introduce a degree of misclassification error in estimates
of coffee consumption due to imprecise definitions of
portion sizes. Such error, however, would likely be non-
differential thus resulting in conservative estimates of as-
sociations. Additionally, NAFLD was not assessed using
the gold standard liver biopsy, as this technique is not
suitable for use in epidemiologic studies. Liver trans-
aminase levels have been shown to be well correlated
with directly-measured liver fat by magnetic resonance
Table 3 Multiple linear regression analysis of the association of caffeinated coffee consumption with markers of liver injury when
individuals consuming ≥ 1 alcoholic drink/day were excluded
Outcome per unit increase
in caffeinated coffee
ALTab ASTab Fetuin-Aac NAFLD liver fat
scoread
β (95 % CI) p value β (95 % CI) p value β (95 % CI) p value β (95 % CI) p value
Model 1 −0.10 (−0.17, −0.03) 0.0046 −0.05 (−0.10, −0.01) 0.0280 0.02 (−0.04, 0.08) 0.47 −0.07 (−0.13, −0.02) 0.0070
Model 2 −0.11 (−0.18, −0.03) 0.0037 −0.05 (−0.10, −0.00) 0.0420 0.02 (−0.04, 0.08) 0.54 −0.06 (−0.11, −0.01) 0.0189
Model 3 −0.11 (−0.18, −0.04) 0.0037 −0.05 (−0.10, −0.00) 0.0330 0.03 (−0.04, 0.09) 0.41 −0.06 (−0.11, −0.01) 0.0298
Model 4 −0.08 (−0.16, −0.00) 0.0400 −0.03 (−0.08, 0.02) 0.20 0.03 (−0.04, 0.09) 0.44 −0.03 (−0.07, 0.02) 0.27
Model 1: Age, sex, ethnicity
Model 2: Adjusted as in model 1 + energy intake, energy expenditure, education, BMI, smoking, alcohol consumption
Model 3: Adjusted as in model 2 + whole grain consumption, vegetable intake, fruit intake, % energy from saturated fat, % energy from polyunsaturated fat,
decaffeinated coffee consumption, regular soft drinks, lemonade/sweetened mineral water
Model 4: Adjusted as in model 3 + insulin sensitivity
aLog transformation;b n = 827 with slight variation across models;cn = 541 with slight variation across models; dn = 821 with slight variation across models
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spectroscopy, and the NAFLD liver fat score is a vali-
dated, non-invasive method found to be more robust
than similar predictive scores for identifying NAFLD,
making these techniques appropriate alternatives to liver
biopsy [24, 25, 47].
Finally, it should be emphasized that the magnitude of
associations of caffeinated coffee with liver markers in
the present study was modest, a finding that may be due
in part to misclassification of consumption (which would
dilute effect estimates, as described above), as well as the
relatively modest consumption of coffee in the popula-
tion, particularly in comparison to other studies investi-
gating associations of coffee with markers of liver injury;
the majority of which reported average consumption of
1 or more cups of coffee/day. In the present study, the
median (IQR) of caffeinated and decaffeinated coffee in-
take were 0.4 (0–0.8) servings/day and 0 (0–0.03) serv-
ings/day, respectively. Conducting this study in a
population in which coffee types were being consumed
at higher levels may have improved our ability to detect
associations of coffee with outcome variables particularly
if coffee’s beneficial effects are exerted only at higher
doses. This may be particularly important for decaffein-
ated coffee since consumption of this type was quite low
in this cohort.
Conclusions
Results of this multi-ethnic cross-sectional epidemio-
logic study identified significant inverse associations of
caffeinated coffee consumption with liver transaminases
ALT and AST, and the NAFLD liver fat score. There
were no significant associations of decaffeinated coffee
intake with markers of liver injury. These findings con-
tribute to a greater understanding of the relationship of
coffee consumption with liver injury and in turn, suggest
that this relationship may mediate the well-established
inverse association of caffeinated coffee and the risk of
T2DM.
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